Star Scientific, Inc. through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reported that scientists from its research partner, the Roskamp Institute, presented new research October 14 & 15 indicating that supplementation with anatabine, the active ingredient in the Company's Anatabloc(R) dietary supplement, has the potential to alleviate the negative consequences of traumatic brain injury (TBI). These findings were presented during a press conference and also at a nanosymposium presentation at Neuroscience 2012, the 42(nd) annual meeting of the Society for Neuroscience.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
2020 | Rock Creek Pharmaceuticals, Inc. Went Out of Business | CI |
2020 | Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 17.04K | |
+48.79% | 780B | |
+41.76% | 627B | |
+19.43% | 334B | |
+7.18% | 296B | |
+17.60% | 244B | |
-0.41% | 217B | |
+11.54% | 214B | |
+4.53% | 161B | |
-3.92% | 159B |
- Stock Market
- Equities
- RCPIQ Stock
- News Rock Creek Pharmaceuticals, Inc.
- Rock Creek Pharmaceutical, Inc.'s Research Presented at Neuroscience 2012